Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
Visitors to your website might want directions to your store via Google Maps, a roundup of your social media feeds, and a ...
Although atrial fibrillation/atrial flutter (AFib/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM), a post hoc analysis of the ATTR-ACT study, published April 30 in ...
Researchers conducted a retrospective cohort study using data from the US Veterans Health Administration to quantify the time from HF diagnosis to ATTR-CM diagnosis and identify predictors of delays ...
Recognizing a need to update the 2021 criteria for monitoring disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a group of international experts shared new proposed ...
Patients diagnosed with wild-type ATTR-CM on or before 65 years of age had better survival after diagnosis compared to patients who were diagnosed after 65 years. Wild-type transthyretin-mediated ...
Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...
Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
OverTTuRe China研究数据的公布,我们得以重新审视ATTR-CM真实的疾病负担;浙江大学医学院附属第二医院的临床实践为疾病管理提供了参考与借鉴。 转甲状腺素蛋白淀粉样变(ATTR)是一类致命性进展性疾病,因TTR蛋白解离错误折叠形成淀粉样纤维沉积于心脏、神经 ...
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
Between 21.4% and 57.8% of patients from a real-world ATTR-CM cohort would have been eligible to take part in clinical trials testing disease-modifying therapies. Inclusion and exclusion criteria used ...